AirSeal is honored to be selected as 1st first-place winner for the Biotech

Releted Post

AirSeal is selected as a recipient of the first WashU Venture Network Follow-on Investments

April 12, 2025

Our co-founder, Dr. Zayed, was recently interviewed by KMOX Radio

April 1, 2025

AirSeal is awarded a co-investment of $500,000 from Missouri Technology Corporation (MTC)

November 12, 2024

AirSeal is selected as a 2024 Arch Grants recipient, which includes a $75,000 non-dilutive cash award.

November 1, 2024

AirSeal is honored to be selected as 1st first-place winner for the Biotech / Healthtech Semi-Finals in St. Louis competition of 2024 Startup World Cup.

https://www.linkedin.com/posts/techstl_stlouis-biotech-healthtech-activity-7203858820966539264–X1O?utm_source=share&utm_medium=member_desktop

AirSeal is advancing early, accurate diagnosis of cardiovascular diseases through innovative biomarker technology.